Proteasome from the laboratory to the clinic

In the upcoming BCO seminar, the two speakers will navigate from the proteasome-related biology to the clinical applications, specifically using the proteasome inhibitors in multiple myeloma. 

Giada Bianchi, MD
Brigham and Women’s Hospital 
Harvard Medical School

El Bachir Affar, PhD 
Centre de recherche de l'Hôpital Maisonneuve-Rosemont
University of Montreal

Register now

Dr. El Bachir Affar is a professor in the Department of Medicine at the University of Montréal and the Hospital Maisonneuve-Rosemont Research Centre.  Dr. Affar is an investigator of the Fonds de la Recherche du Québec en Santé (FRQ-S) and the Canadian Institutes of Health Research (CIHR). His research focuses on understanding how the ubiquitin proteasome system regulates chromatin-associated processes, and how defects in these signaling events underlie human diseases notably cancer (PMID: 34848715 & 30349006).  

Dr. Giada Bianchi is a physician-scientist and associate physician with the Hematology Division of the Brigham and Women’s Hospital, Boston, MA. She is Associate Director of the Amyloidosis Program at Brigham and Women’s Hospital/Dana Farber Cancer Institute and Instructor in Medicine at Harvard Medical School, Boston, MA. The research interest of the Bianchi lab is to discover the mechanisms regulating protein homeostasis in physiologic and pathologic states of plasma cell differentiation and the role that proteostasis plays in determining plasma cell fate (PMID: 34649278 & 19164601). 

The Basic and Clinical Oncology Seminar Series (BCO) is a joint initiative by the IRCM and LDI institutes in Montreal. These monthly seminars will feature a clinical (MD or MD/PhD) and a basic scientist (PhD) speaker, both working on the same cancer or theme. The goal is to create a dialogue between those at the bench and their peers at the bedside. The long-term goal is to initiate and expedite collaborations like sharing samples and exchanging expertise. Each seminar is made of two talks, each for 15 minutes and 5 minutes of questions. The remaining 10 minutes is for open discussion.